By PR Newswire, October 24, 2013, 09:39:00 AM EDT
Editor Note: For more information about this release, please scroll to bottom.
LONDON, October 24, 2013 /PRNewswire/ --
On Wednesday, October 23, 2013, all three benchmark indexes of the US equity market declined, with the Dow Jones Industrial Average, the S&P 500, and the NASDAQ Composite falling by 0.35%, 0.47%, and 0.57%, respectively. Shares in the healthcare sector ended on a mixed note, even as the broader market declined. The major movers included Teva Pharmaceutical Industries Ltd. (NYSE:TEVA), Dynavax Technologies Corporation (NASDAQ:DVAX), Covidien PLC (NYSE:COV), and Valeant Pharmaceuticals International Inc. (NYSE:VRX). AAAResearchReports.com initiated preliminary technical research on TEVA, DVAX, COV, and VRX. These free reports are accessible by signing today at:
Shares in Teva Pharmaceutical Industries Ltd edged lower on Wednesday, tracking losses in the broader market. The company's shares fluctuated between $39.98 and $40.43 before closing the day 0.52% lower at $40.18. A total of 2.44 million shares were traded, which is less than the daily average volume of 3.88 million. The company's shares are up 5.71% in the previous one month and 0.45% in the last three trading sessions, outperforming the S&P 500, which has gained 2.62% and 0.11% during the respective periods. Moreover, Teva Pharmaceutical Industries Ltd's stock is currently trading above its 50-day and 200-day moving averages of $38.78 and 38.92, respectively. The free technical analysis on TEVA is available by signing up at:
Dynavax Technologies Corp.'s shares closed at $1.15, down 2.95%, after oscillating between $1.13 and $1.21 during Wednesday's trading session. A total of 1.65 million shares were traded, which is below the daily average volume of 1.85 million. The company's shares have declined 3.44% in the previous one month, compared to a gain of 2.62% in the S&P 500 during the same period. Furthermore, Dynavax Technologies Corp.'s stock is trading below its 50-day and 200-day moving averages of $1.24 and $1.92, respectively. Register now to download free research on DVAX at:
Covidien PLC's stock closed Wednesday's session 0.92% higher at $64.76, after hitting a new 52-week high of $65.04. The company's shares oscillated between $63.92 and $65.04 during the trading session. A total of 2.41 million shares were traded, which is above the daily average volume of 2.16 million. The company's shares have gained 5.68% in the previous three months and 3.43% in the last one month, outperforming the S&P 500, which has gained 3.19% and 2.62% during the respective periods. Further, Covidien PLC's stock is trading above its 50-day and 200-day moving averages of $61.33 and $59.56, respectively. A free report on COV can be accessed by registering at:
Shares in Valeant Pharmaceuticals International Inc. posted gains on Wednesday, finishing at $114.37, up 1.64% from the previous day's closing price of $112.53. The company's shares oscillated between $111.54 and $114.60 during the trading session. A total of 1.16 million shares were traded, which is above the daily average volume of 1.15 million. The company's stock has surged 26.39% in the previous three months and 10.95% in the last one month, compared to a gain of 3.19% and 2.62% in the S&P 500 during the respective periods. Moreover, Valeant Pharmaceuticals International Inc.'s stock is trading above its 50-day and 200-day moving averages of $104.15 and $84.14, respectively. Register with AAA Research Reports and download research on VRX for free at:
This is not company news. We are an independent source and our views do not reflect the companies mentioned.
Information in this release is fact checked and produced on a best efforts basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com.
For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com.
Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration.
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Ananya Ghosh, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE AAA Research Reports